Biogen Idec to pay up to $562.5M for Stromedix
NEW YORK (AP) — Biogen Idec Inc. said Tuesday it will pay as much as $562.5 million to acquire Stromedix Inc., a biotechnology firm that is developing treatments for conditions like idiopathic pulmonary fibrosis.
Biogen said it will pay $75 million upfront, and it could pay as much as $487.5 million more based on the development and regulatory approval of drugs developed by Stromedix. Its most advanced drug is i...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
